SCHEMBL4948501

SCHEMBL4948501

CCOc1cc(N(CCC(=O)O)C(=O)CC)ccc1OC

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 1/20 0.44
MAPK1 P28482 1/20 0.44
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
KEAP1 Q14145 1/20 0.41
NFE2L2 Q16236 1/20 0.41
LMNA P02545 1/20 0.40
MCHR1 Q99705 1/20 0.40
PDE4A P27815 5/20 0.40
PDE4B Q07343 5/20 0.40
PDE4C Q08493 5/20 0.40
PDE4D Q08499 5/20 0.40
FFAR1 O14842 1/20 0.40
FFAR4 Q5NUL3 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3199341 0.81 OPRM1 (0.54) ALDH1A1LMNAPDE4B
SCHEMBL3199587 0.79 MTNR1A (0.59) LMNA
SCHEMBL7151743 0.78 MAPK1 (0.50) TSHRL3MBTL1TP53MAPK1KMT2A
SCHEMBL11807879 0.76 CYP3A4 (0.54) L3MBTL1MEN1ALDH1A1KMT2A
SCHEMBL3207994 0.73 LMNA (0.48) TSHRL3MBTL1ALDH1A1KMT2ALMNA
SCHEMBL3199140 0.73 TP53 (0.64) TSHRTP53MEN1ALDH1A1KMT2A
SCHEMBL3673329 0.72 FFAR4 (0.61) TSHRL3MBTL1MEN1KMT2AFFAR1
SCHEMBL18644940 0.72 TSHR (0.47) TSHRL3MBTL1MAPK1ALDH1A1KMT2A
SCHEMBL7995941 0.71 FFAR4 (0.60) TSHRL3MBTL1MEN1KMT2AFFAR1
SCHEMBL28323456 0.70 L3MBTL1 (0.54) TSHRL3MBTL1MEN1KMT2AFFAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080280967-A1 Substituted acylhydroxamic acids and method of reducing TNFalpha levels CELGENE CORPORATION 2008-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280967-A1 Substituted acylhydroxamic acids and method of reducing TNFalpha levels APEH, TNF, ACOX3 TSHR 2216/4885L3MBTL1 1836/4885TP53 4342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.